AKT1 and melanoma: The latest report says that by activating ICD, targeting wee1/akt pathway can lead to the recruitment and activation of immune cells in TME, triggering an inflammatory cascade, so that the “cold” TME of melanoma can be transformed into a “hot” TME responsive to programmed cell death proteins, leading to the complete regression of established tumors (Dinavahi et al., 2022).